William Jacob Savage Sells 5,731 Shares of Disc Medicine (NASDAQ:IRON) Stock

Key Points

• Insider sale: Director William Jacob Savage sold 5,731 shares of Disc Medicine on April 13 at an average price of $66.38 for $380,423.78, trimming his stake by 6.73% to 79,480 shares (he also sold 7,378 shares on Mar 2 and 3,256 on Feb 17).
• Stock and results snapshot: shares traded down to $70.18, with a 50-day/200-day moving average of $64.99/$76.18, a $2.68 billion market cap and a negative P/E (‑11.72); the company reported a Q quarter EPS loss of ($1.62) that beat estimates while revenue was well below expectations.
• Analyst and ownership context: the consensus rating is a "Moderate Buy" with a $104.80 price target (10 buys, 1 hold, 1 sell), and institutional investors own about 83.7% of the stock with several funds recently increasing positions.

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider William Jacob Savage sold 5,731 shares of the business's stock in a transaction on Monday, April 13th. The shares were sold at an average price of $66.38, for a total transaction of $380,423.78. Following the transaction, the insider owned 79,480 shares in the company, valued at approximately $5,275,882.40. This represents a 6.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

William Jacob Savage also recently made the following trade(s):

• On Monday, March 2nd, William Jacob Savage sold 7,378 shares of Disc Medicine stock. The shares were sold at an average price of $65.88, for a total transaction of $486,062.64.
• On Tuesday, February 17th, William Jacob Savage sold 3,256 shares of Disc Medicine stock. The shares were sold at an average price of $62.86, for a total transaction of $204,672.16.

Disc Medicine Stock Down 0.4%

Shares of Disc Medicine stock traded down $0.30 on Wednesday, hitting $70.18. 300,163 shares of the company traded hands, compared to its average volume of 660,190. The company has a 50-day moving average price of $64.99 and a 200 day moving average price of $76.18. The company has a quick ratio of 21.94, a current ratio of 21.94 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a 12-month low of $39.20 and a 12-month high of $99.50. The company has a market cap of $2.68 billion, a PE ratio of -11.72 and a beta of 0.91.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) EPS for the quarter, beating the consensus estimate of ($1.69) by $0.07. The company had revenue of ($19.88) million for the quarter, compared to analysts' expectations of $0.15 million. Sell-side analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Raymond James Financial reaffirmed a "market perform" rating on shares of Disc Medicine in a research note on Thursday, January 15th. Stifel Nicolaus reduced their price objective on shares of Disc Medicine from $125.00 to $110.00 and set a "buy" rating for the company in a research note on Tuesday, February 17th. Morgan Stanley set a $75.00 price objective on shares of Disc Medicine in a research note on Tuesday, February 17th. Truist Financial reduced their price objective on shares of Disc Medicine from $114.00 to $83.00 and set a "buy" rating for the company in a research note on Friday, February 27th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Disc Medicine in a research note on Wednesday, January 21st. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $104.80.

Institutional Investors Weigh In On Disc Medicine

Institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Disc Medicine by 22.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company's stock worth $756,000 after acquiring an additional 2,807 shares during the last quarter. Millennium Management LLC lifted its position in Disc Medicine by 1,277.1% during the 1st quarter. Millennium Management LLC now owns 108,499 shares of the company's stock worth $5,386,000 after acquiring an additional 100,620 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Disc Medicine by 3.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company's stock worth $4,793,000 after acquiring an additional 3,454 shares during the last quarter. Legal & General Group Plc lifted its position in Disc Medicine by 18.0% during the 2nd quarter. Legal & General Group Plc now owns 24,097 shares of the company's stock worth $1,276,000 after acquiring an additional 3,682 shares during the last quarter. Finally, Invesco Ltd. lifted its position in Disc Medicine by 21.6% during the 2nd quarter. Invesco Ltd. now owns 16,817 shares of the company's stock worth $891,000 after acquiring an additional 2,983 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company's stock.

About Disc Medicine

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.